Close Menu

NEW YORK (GenomeWeb News) – Roche today announced that it has teamed with the Innovative Medicines Initiative to lead a consortium of industry and academic partners that will use stem cells for drug discovery research.

The project, called StemBANCC, will be initiated and coordinated by Roche, managed by Oxford University, and include 10 pharmaceutical companies and 23 academic institutions. Researchers involved in the effort will use human induced pluripotent stem cells as tools for drug discovery with the goal of developing human disease models and enhancing drug development.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Sep
02
Sponsored by
ACD

This webinar will discuss the use of digital spatial profiling to test a gene therapy for CDKL5 deficiency disorder (CDD), a rare X-linked neurodevelopmental disease that causes severe seizures, global developmental delay, and limits a patient’s ability to communicate.

Sep
03
Sponsored by
Illumina

This webinar will provide an overview of how the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado implemented a preemptive pharmacogenomic screening program via a large-scale research biobank and a robust biocomputing system.

Sep
17
Sponsored by
Thermo Fisher Scientific

The prevalence of developmental disability among US children aged 3 to 17 years increased between 2009 and 2017, with as many as 1 in 6 children in the US reported to have a developmental disability diagnosis.